B
Bull
Bull · 25%ABP
$0.24
Scenario price
$0.522
-0.181 (-34.76%)At close
Loading chart…
- High
- 0.780
- Open
- 0.759
- VWAP
- 0.61
- Volume
- 3.26M
- Mkt Cap
- —
- Low
- 0.517
- Amount
- 1.98M
- EV/EBITDA, TTM
- 0.00
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
AI analysis of ABPRO Holdings Inc (ABP)
SellABPRO Holdings Inc (ABP) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits weak financial performance, bearish technical indicators, and lacks positive catalysts or strong trading signals to justify a buy decision.
Valuation Metrics
The current forward P/E ratio for ABPRO Holdings Inc (ABP) is -0.63, compared to its 5-year average forward P/E of -1.48.
Alphio AI Price Scenarios for ABP
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
9.502-12BenzingaFastly Reports Strong Quarterly Earnings Exceeding Expectations
4.502-10BenzingaU.S. Stocks Mixed in Morning Trading
9.502-10BenzingaCredo Technology Raises Revenue Guidance Significantly
9.012-15GlobenewswireAbpro Submits IND for ABP-102/CT-P72, Initiating Phase 1 Clinical Trial
9.012-15NewsfilterAbpro Submits IND Application for ABP-102/CT-P72, Targeting HER2-Positive Cancers
ABP FAQ — answered by Alphio AI
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD). It operates in the Healthcare sector.
ABPRO Holdings Inc (ABP) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits weak financial performance, bearish technical indicators, and lacks positive catalysts or strong trading signals to justify a buy decision.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.